Regulation - Patents

Filter

Current filters:

Patents

Popular Filters

1 to 25 of 69 results

Update: Negotiations on EU-Canada Free Trade Agreement concluded

Update: Negotiations on EU-Canada Free Trade Agreement concluded

29-09-2014

Canadian trade group Research-Based Pharmaceutical Companies (Rx&D) expressed its support to the government…

CanadaEuropeGenericsMarkets & MarketingPatentsPoliticsRegulation

Despite limited size, Chile's pharma market offers growing opportunity

23-09-2014

By the end of 2014, the Chilean pharmaceutical market is expected to be worth $2 billion, increasing…

ChileHealthcareMarkets & MarketingPatentsPharmaceuticalRegulation

Australia's federal court rules that companies can patent genetic material

Australia's federal court rules that companies can patent genetic material

05-09-2014

The Full Bench of the Federal Court of Australia has decided a private company may hold a patent on a…

AustraliaBiotechnologyIntellectual propertyLegalPatentsPharmaceutical sciencesRegulation

Actavis confirms patent challenge for generic Neupro

Actavis confirms patent challenge for generic Neupro

23-08-2014

Ireland-headquartered generics major Actavis on Friday confirmed that it has filed an Abbreviated New…

ActavisGenericsLegalNeuproNeurologicalPatentsRegulationUCBUSA

Actavis confirms patent challenge to Duchesnay’s Diclegis

Actavis confirms patent challenge to Duchesnay’s Diclegis

12-07-2014

Ireland-based generics major Actavis on Friday confirmed that it has filed an Abbreviated New Drug Application…

ActavisDiclegisDuchesnayGenericsPatentsRegulationUSAWomen's Health

Teva files citizen petition with FDA regarding Copaxone complexity

Teva files citizen petition with FDA regarding Copaxone complexity

03-07-2014

Teva Pharmaceutical Industries says it has filed a citizen petition regarding the approvability of purported…

CopaxoneLegalNeurologicalPatentsPharmaceuticalRegulationTeva Pharmaceutical IndustriesUSA

Vivus says Actavis has filed ANDA for generic Qsymia

Vivus says Actavis has filed ANDA for generic Qsymia

10-05-2014

US drug developer Vivus disclosed on Friday that the company had received notice from generics major…

ActavisGenericsMetabolicsPatentsQsymiaRegulationUSAVivus

EGA calls for removal of barriers to competition and free trade for generics

EGA calls for removal of barriers to competition and free trade for generics

19-03-2014

The European Union must remove barriers to competition and free trade by introducing common sense reforms…

BiosimilarsEuropeGenericsMarkets & MarketingPatentsRegulation

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

25-11-2013

US biotech company Biogen Idec saw its shares leap 10% to an all-time high of nearly $278 on Friday,…

Biogen IdecBiotechnologyEuropeNeurologicalPatentsRegulationTecfidera

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent

14-11-2013

US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

Indian pharmaceutical market to reach $56 billion by 2020, says GlobalData

03-10-2013

Driven by the country’s growing economy and population income, the Indian pharmaceutical market will…

Asia-PacificMarkets & MarketingPatentsPharmaceuticalRegulation

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Actavis confirms patent challenge on Bayer's Safyral

06-06-2013

USA-based generics major Actavis (NYSE: ACT) yesterday (June 5) confirmed that it has filed an Abbreviated…

ActavisBayerGenericsPatentsRegulationReproductiveSafyralWomen's Health

Market access barriers for multinationals, but Argentina still offers attractive pharma opportunities

31-05-2013

Several barriers impede market access but the regulatory landscape in Argentina is changing and attractive…

BiotechnologyMarkets & MarketingPatentsPharmaceuticalRegulationSouth America

Biogen Idec sees EU launch delay for Tecfidera on patent issues

31-05-2013

In a filing with the Securities and Exchange Commission, US biotech firm Biogen Idec (Nasdaq: BIIB) said…

Biogen IdecBiotechnologyEuropeMarkets & MarketingNeurologicalPatentsRegulationTecfidera

Ahead of 2013 federal election, trade group makes plea for fixing Australia's PBS listing system

27-05-2013

Pharma trade group Medicines Australia today (May 27) launched its 2013 Federal Election document, calling…

Asia-PacificHealthcarePatentsPharmaceuticalPoliticsPricingRegulation

Argentina's pharma market to almost triple over one decade, says GlobalData

24-04-2013

Argentina's pharmaceutical market is expected to grow from a value of around $5.6 billion in 2012 to…

GenericsMarkets & MarketingPatentsPharmaceuticalProductionRegulationSouth America

1 to 25 of 69 results

Parexel

Parexel

Back to top